Nexium Control 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
IAIN/0039 
A.5.a - Administrative change - Change in the name 
24/04/2023 
and/or address of a manufacturer/importer 
responsible for batch release 
amended 
on 
Annex II and 
PL 
N/0037 
Minor change in labelling or package leaflet not 
10/01/2022 
17/02/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
  
 
 
 
 
 
 
PSUSA/1269/
Periodic Safety Update EU Single assessment - 
28/10/2021 
n/a 
PRAC Recommendation - maintenance 
202103 
esomeprazole 
IB/0035 
C.I.z - Changes (Safety/Efficacy) of Human and 
08/02/2021 
17/02/2022 
SmPC, 
Veterinary Medicinal Products - Other variation 
Labelling and 
PL 
T/0033 
Transfer of Marketing Authorisation 
13/10/2020 
10/11/2020 
SmPC, 
Labelling and 
PL 
IB/0032 
B.III.1.a.1 - Submission of a new/updated or 
23/10/2020 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
IB/0029/G 
This was an application for a group of variations. 
10/06/2020 
10/11/2020 
SmPC, 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
Labelling and 
PL 
IB/0031/G 
This was an application for a group of variations. 
28/04/2020 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
Page 2/9
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
IB/0030/G 
This was an application for a group of variations. 
31/03/2020 
n/a 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
IA/0028 
B.II.e.7.a - Change in supplier of packaging 
02/10/2019 
n/a 
components or devices (when mentioned in the 
dossier) - Deletion of a supplier 
IA/0027 
A.7 - Administrative change - Deletion of 
31/07/2019 
n/a 
Page 3/9
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturing sites 
IA/0026 
A.5.b - Administrative change - Change in the name 
18/01/2019 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IB/0025/G 
This was an application for a group of variations. 
08/01/2019 
n/a 
B.II.d.1.g - Change in the specification parameters 
and/or limits of the finished product - Addition or 
replacement (excluding biological or immunological 
product) of a specification parameter wit its 
corresponding test method as a result of a safety or 
quality issue 
B.II.d.1.g - Change in the specification parameters 
and/or limits of the finished product - Addition or 
replacement (excluding biological or immunological 
product) of a specification parameter wit its 
corresponding test method as a result of a safety or 
quality issue 
IB/0024 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
05/12/2018 
05/12/2019 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
T/0023 
Transfer of Marketing Authorisation 
17/08/2018 
28/09/2018 
SmPC, 
Labelling and 
PL 
IB/0022/G 
This was an application for a group of variations. 
05/07/2018 
n/a 
Page 4/9
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Including batch control/testing 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
Page 5/9
 
 
 
 
 
 
R/0021 
Renewal of the marketing authorisation. 
26/04/2018 
25/06/2018 
SmPC, 
Labelling and 
PL 
IAIN/0020 
B.II.b.1.a - Replacement or addition of a 
21/11/2017 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IA/0019 
B.III.2.b - Change to comply with Ph. Eur. or with a 
08/09/2017 
n/a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
IB/0018 
C.I.z - Changes (Safety/Efficacy) of Human and 
29/08/2017 
25/06/2018 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
X/0016 
Annex I_2.(d) Change or addition of a new 
21/04/2017 
15/06/2017 
SmPC, 
pharmaceutical form 
Labelling and 
PL 
IAIN/0017 
C.I.z - Changes (Safety/Efficacy) of Human and 
27/10/2016 
15/06/2017 
SmPC 
Veterinary Medicinal Products - Other variation 
PSUSA/1269/
Periodic Safety Update EU Single assessment - 
27/10/2016 
n/a 
PRAC Recommendation - maintenance 
201603 
esomeprazole 
IB/0014 
C.I.z - Changes (Safety/Efficacy) of Human and 
23/11/2015 
26/05/2016 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IA/0013 
A.5.b - Administrative change - Change in the name 
23/10/2015 
n/a 
and/or address of a manufacturer/importer of the 
Page 6/9
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IA/0011 
A.4 - Administrative change - Change in the name 
13/08/2015 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
IAIN/0010 
B.II.b.1.a - Replacement or addition of a 
23/07/2015 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
N/0009 
Minor change in labelling or package leaflet not 
10/07/2015 
26/05/2016 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
IAIN/0008 
A.5.a - Administrative change - Change in the name 
11/05/2015 
26/05/2016 
Annex II and 
and/or address of a manufacturer/importer 
responsible for batch release 
PL 
IB/0007 
C.I.11.z - Introduction of, or change(s) to, the 
08/01/2015 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IAIN/0006 
B.II.b.1.a - Replacement or addition of a 
04/12/2014 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0005 
C.I.z - Changes (Safety/Efficacy) of Human and 
24/06/2014 
27/05/2015 
SmPC, 
Veterinary Medicinal Products - Other variation 
Labelling and 
PL 
Page 7/9
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T/0004 
Transfer of Marketing Authorisation from 
07/03/2014 
21/03/2014 
SmPC, 
AstraZeneca AB to Pfizer Consumer Healthcare Ltd. 
Transfer of Marketing Authorisation 
Labelling and 
PL 
II/0001 
C.I.z - Changes (Safety/Efficacy) of Human and 
23/01/2014 
21/03/2014 
SmPC and 
The MAH summarised within this variation application 
Veterinary Medicinal Products - Other variation 
Labelling 
efficacy results of esomeprazole 20 mg from the pivotal 
IAIN/0003/G 
This was an application for a group of variations. 
25/11/2013 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
trials on the treatment of symptoms of reflux including 
heartburn and acid regurgitation over a 24 hour period 
during the first two weeks of usage extracted from the 
Clinical Study Reports. 
This data as per agreed update to 5.1 of the SmPC was 
considered to be valuable information to healthcare 
professionals and consumers on the clinical benefits to be 
expected from the once daily dosing of this medicine, 
during the first two weeks of treatment. 
In accordance the outer package text was amended 
introducing temporary the statement “new”, the statements 
“lasts 24 hours”, a placeholder for a website and an 
adaptation of the indication statement in line with the 
SmPC. 
Page 8/9
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0002/G 
This was an application for a group of variations. 
29/10/2013 
21/03/2014 
Annex II and 
PL 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Including batch control/testing 
Page 9/9
 
 
 
 
 
 
 
 
 
